Table 1.
Demographic and clinical characteristics of patients with ANCA-associated glomerulonephritis
| Variable | Total, n = 147 |
|---|---|
| Age, mean (SD), years | 60.2 (16) |
| Male, n/N (%) | 85/147 (57.8) |
| ANCA positive, n/N (%) | 112/147 (76.2) |
| MPO, n/N (%) | 95/147 (64.6) |
| PR3, n/N (%) | 18/47 (12.2) |
| Extrarenal involvement, n/N (%) | 65/147 (44.2) |
| BVAS score, mean (SD) | 15.3 (4.4) |
| Dialysis at onset, n/N (%) | 52/147 (35.3) |
| sCr, median (IQR), mmol/L | 344.7 (194–574) |
| eGFR (CKD-EPI), median (IQR), mL/min/1.73 m2 | 14.7 (8–27.1) |
| Urinary protein excretion, median (IQR), g/day | 1.5 (0.7–3) |
| Immunosuppressive therapy, n (%) | 147 (100) |
| Steroids plus CYC, n/N (%) | 127/147 (86.3) |
| Steroids + other agents, n (%) | 20 (13.6) |
| Treatment response, n/N (%) | 94/135 (69.6) |
| Follow-up period, median (IQR), months | 41 (9.6–104) |
| Evolution to ESRD in the follow-up, n/N (%) | 48/147 (32.7) |
| Death, n/N (%) | 51/147 (34.7) |
| Death or ESRD, n (%) | 74/147 (50.3) |